Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a negative trailing P/E of -1.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -57.15%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -17.4 | -0.24 | 38.97 | 181.86 | - |
| 2017 | -11.0 | -0.33 | 6.17 | 146.00 | - |
| 2018 | -6.0 | -0.12 | 12.09 | 69.03 | - |
| 2019 | -4.9 | -0.45 | 56.66 | 9.65 | - |
| 2020 | -0.9 | -0.03 | 2.16 | 24.81 | - |
| 2021 | -1.7 | 0.02 | 1.10 | 85.93 | - |
| 2022 | -0.2 | 0.03 | 0.42 | 0.00 | - |
| 2023 | -0.6 | -0.37 | -3.78 | 0.00 | - |
| 2024 | -3.2 | 0.05 | 0.90 | 0.00 | - |
| 2025 | -1.4 | -0.02 | 0.73 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-14.58 | $1.91M | $-20M | -1046.3% |
| 2017 | $-19.38 | $2.44M | $-32.42M | -1328.6% |
| 2018 | $-29.30 | $4.82M | $-55.67M | -1154.5% |
| 2019 | $-32.47 | $36.14M | $-69.15M | -191.3% |
| 2020 | $-42.74 | $3.94M | $-111.3M | -2827% |
| 2021 | $-11.11 | $881.71K | $-45.55M | -5166.4% |
| 2022 | $-13.39 | $0.00 | $-55.83M | - |
| 2023 | $-10.31 | $0.00 | $-44.6M | - |
| 2024 | $-3.68 | $0.00 | $-40.21M | - |
| 2025 | $-5.90 | $0.00 | $-78.54M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.58 | $-5.46 – $-2.83 | $2M | $2M – $2M | 8 |
| 2027 | $-4.94 | $-6.90 – $-4.02 | $6.63M | $6.63M – $6.63M | 7 |
| 2028 | $-5.33 | $-6.85 – $-2.76 | $21.9M | $21.9M – $21.9M | 7 |
| 2029 | $-4.61 | $-4.61 – $-4.61 | $117.47M | $117.47M – $117.47M | 2 |
| 2030 | $-0.72 | $-0.72 – $-0.72 | $284.78M | $284.78M – $284.78M | 5 |
